Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), presented clinical data at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference highlighting the accuracy and clinical utility of its AlzoSure® Predict prognostic blood test for Alzheimer’s Disease (AD), setting the stage for commercialization in the U.S. beginning in 2023.
In the presentation by Diadem Chief Medical Officer Sam Agus MD, on December 2nd, Diadem discussed how AlzoSure® Predict can aid pharmaceutical and biotechnology companies for screening, enrichment and stratification of patient populations to facilitate Alzheimer’s disease clinical trials. Use of the test enables drug developers to identify individuals who will experience a decline to Alzheimer’s dementia up to six years in advance of diagnosis with high confidence, regardless of their cognitive, amyloid, or tau measurement status at the time of testing. This type of patient stratification can improve clinical trial recruitment and the odds of success, as it ensures that patients participating in the trials have a very high probability of developing full-blown AD.
Also Read: Armis Named Clear Leader in SPARK Matrix for Connected Medical Device Security Solutions
Additionally, Dr. Agus discussed the utility of the test as a screening tool to enable physicians to identify those individuals at high risk of developing AD very early in the disease process, when therapies may be most effective. The likely approval of new drugs such as lecanemab from Eisai and Biogen, which shows promising signs of slowing cognitive decline in early AD, highlights the need for accurate and economical screening tools to select patients most likely to benefit from early treatment.
“This is an exciting time in the battle against Alzheimer’s disease,” said Paul Kinnon, CEO of Diadem. “Advances in AD diagnosis and therapy are finally providing hope that we can begin to slow or stop the progression of this terrible disease, which impacts so many individuals and families. We see AlzoSure® Predict playing a key role in this progress, with its wide potential accessibility and its ability to enhance AD clinical trials and to identify individuals at high risk for progression to AD. As we expected, global market research we are in the process of conducting is showing that both individuals and physicians indicate strong interest in early access to better diagnostic tools for Alzheimer’s.”
SOURCE: PR Newswire